Navigation Links
BeneChill Launches European Study of Intra-Arrest Cooling
Date:2/3/2009

SAN DIEGO, Feb. 3 /PRNewswire/ -- BeneChill, Inc. (www.benechill.com) today announced the start of the PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study. This randomized study will determine whether intra-nasal cooling using BeneChill's RhinoChill device during resuscitation increases patient resuscitation and survival rates.

The PRINCE study is being conducted as a post-market approval study in Europe. The company received CE marking for the RhinoChill system in 2007.

The non-invasive, portable, and easy-to-use RhinoChill Device is used without external power for rapid therapeutic patient cooling. This system uses a nasal catheter to deliver a proprietary inert coolant to the nasal cavity to reduce temperature in clinically indicated conditions. Current uses of cooling technologies include ischemic events such as cardiac arrest, stroke, and traumatic brain injury. Unlike other cooling devices, the RhinoChill device is easily utilized in emergency field settings.

As part of the upcoming study, patients will receive either advanced cardiac life support measures (ACLS) alone or ACLS supplemented by intra-nasal cooling. The study will be conducted in Belgium, Germany, Italy and Sweden over the next 6-9 months.

"Out-of-hospital cardiac arrest is a significant cause of death," said BeneChill founder/CEO Denise Barbut, MD MRCP. "Mild hypothermia induced after resuscitation from cardiac arrest has been shown to improve survival in humans. Given that our team previously demonstrated the cooling efficacy of our technology in clinical trials around the globe, the PRINCE study is the next logical step."

BeneChill COO Allan Rozenberg, PhD, noted at today's announcement: "Earlier initiation of cooling in animals has a great impact on their survival. In randomized pig studies, for example, we've seen dramatically higher survival rates when intra-nasal cooling has been initiated during resuscitation."

"The RhinoChill Device uses the nasal cavity for cooling," Dr. Rozenberg stressed, noting "This is advantageous since the nasal cavity allows easy access into the body, is in close proximity to the brain, and is a natural heat exchanger."

About BeneChill

BeneChill is a venture capital funded medical device company based in San Diego, CA. The company is developing products in the therapeutic hypothermia arena with a focus on rapid, non-invasive cooling for use in the field. The RhinoChill System is an investigational device in the United States, and is limited by US law to investigational use only.


'/>"/>
SOURCE BeneChill
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
2. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
3. UPMC Health Plan Launches New Personal Health Record
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
10. Actavis Launches Carvedilol Tablets in the U.S.
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... and high-level training standards for healthcare treatment providers who treat the full spectrum ... Presidents Council. , The Presidents Council consists of the leading eating disorder ...
(Date:1/23/2017)... ... , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of ... making new water infrastructure a number one priority. “As we usher in a new ... to become a top priority of our new political change agents.” Kleyne pointed out ...
(Date:1/23/2017)... ... ... METTLER TOLEDO has announced the availability of a new ... . , Crystallization is a common step used during the synthesis ... spend more time developing better intermediate and final crystallization steps. By adopting ...
(Date:1/23/2017)... Aliso Viejo, California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set ... shaky camera to create dynamic looks in Final Cut Pro X," said Christina Austin - ... movement of up to two layers of text with video footage. ProRandom works by ...
(Date:1/23/2017)... ... 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) has ... for women of all ages. The staff of Gynecology Associates of Gwinnett ... from routine health screenings to diagnosing and treating female concerns including menopause, urinary ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... Ahead of today,s trading session, Stock-Callers.com draws investors, attention ... the close: Kite Pharma Inc. (NASDAQ: KITE ), BioPharmX ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to a ... January 20 th , 2017, down on the day by about ... now at: ...
(Date:1/23/2017)... January 23, 2017 Longer life expectancy and rising ... global market for medical device technologies. BCC Research reveals in ... Asia-Pacific region, should see strong growth due to rising ... incomes. Continue Reading ... ...
Breaking Medicine Technology: